On-Demand CE for Nurses

Earn CME on your time and at your own pace with these on-demand activities

New and Emerging ALK/ROS1/NTRK-Targeted Agents in NSCLC: Addressing Treatment Resistance and CNS Metastases

CE Information
1.0 CME credit
Completion Time
60 minutes
Available Until
January 20, 2024
Posted By
HMP Global
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.

Overview

Specialties
Hematology / Oncology
Clinical Topics
Lung Cancer

This on-demand webcast is available with synchronized slides and video/audio.

To be eligible for credit, participants must complete the educational activity, complete the 4-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: January 20, 2023.
Expiration Date: January 20, 2024. 
Estimated Time to Complete: 1.00 hour

There is no fee associated with this activity.

Learning Objectives

After participating in this activity, learners should be better able to:

  • Assess guideline recommendations, testing techniques, and clinical applications for molecular profiling to identify patients who will benefit from ALK, ROS1, or NTRK-targeted therapy
  • Evaluate clinical efficacy and safety data for new and emerging ALK, ROS1, and NTRK-targeted agents against treatment resistance and CNS metastases
  • Utilize adverse event management strategies to optimize treatment efficacy and mitigate treatment risks

CE Information

This activity offers 1.0 CME credit to attendees.


Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity